Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

BACKGROUND: Subcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis (RRMS), and to reduce T1-hypointense lesion formation and the proportion of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L., Calabresi, Peter A., Kieseier, Bernd C., Liu, Shifang, You, Xiaojun, Fiore, Damian, Hung, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301356/
https://www.ncbi.nlm.nih.gov/pubmed/28183276
http://dx.doi.org/10.1186/s12883-017-0799-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301356/
https://www.ncbi.nlm.nih.gov/pubmed/28183276
http://dx.doi.org/10.1186/s12883-017-0799-0

Ejemplares similares